Northern Trust Corp lifted its holdings in shares of Achaogen, Inc. (NASDAQ:AKAO) by 619.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 341,367 shares of the biopharmaceutical company’s stock after buying an additional 293,920 shares during the quarter. Northern Trust Corp owned approximately 0.95% of Achaogen worth $7,418,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in the company. TimesSquare Capital Management LLC raised its stake in shares of Achaogen by 106.7% during the 2nd quarter. TimesSquare Capital Management LLC now owns 1,088,300 shares of the biopharmaceutical company’s stock worth $23,649,000 after buying an additional 561,700 shares during the period. Vanguard Group Inc. raised its stake in shares of Achaogen by 11.2% during the 1st quarter. Vanguard Group Inc. now owns 1,066,701 shares of the biopharmaceutical company’s stock worth $26,913,000 after buying an additional 107,406 shares during the period. Franklin Resources Inc. acquired a new position in shares of Achaogen during the 2nd quarter worth approximately $8,692,000. Spark Investment Management LLC raised its stake in shares of Achaogen by 11.6% during the 2nd quarter. Spark Investment Management LLC now owns 236,700 shares of the biopharmaceutical company’s stock worth $5,143,000 after buying an additional 24,600 shares during the period. Finally, Candriam Luxembourg S.C.A. raised its stake in shares of Achaogen by 149.0% during the 2nd quarter. Candriam Luxembourg S.C.A. now owns 200,555 shares of the biopharmaceutical company’s stock worth $4,358,000 after buying an additional 120,000 shares during the period. 84.18% of the stock is owned by institutional investors and hedge funds.
In other Achaogen news, COO Blake Wise sold 3,576 shares of the company’s stock in a transaction on Tuesday, September 26th. The stock was sold at an average price of $15.99, for a total value of $57,180.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.36% of the stock is owned by corporate insiders.
Shares of Achaogen, Inc. (AKAO) opened at $13.29 on Friday. The company has a current ratio of 6.99, a quick ratio of 8.37 and a debt-to-equity ratio of 0.08. Achaogen, Inc. has a 12-month low of $4.26 and a 12-month high of $27.79.
Achaogen (NASDAQ:AKAO) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.13). The company had revenue of $0.58 million during the quarter, compared to analysts’ expectations of $2.09 million. Achaogen had a negative net margin of 593.61% and a negative return on equity of 80.44%. The firm’s quarterly revenue was down 96.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.41) earnings per share. equities research analysts predict that Achaogen, Inc. will post -2.97 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.themarketsdaily.com/2017/11/12/achaogen-inc-akao-shares-bought-by-northern-trust-corp.html.
Several research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Achaogen in a research note on Thursday. Mizuho reaffirmed a “buy” rating and set a $28.00 target price on shares of Achaogen in a research note on Thursday. Stifel Nicolaus dropped their price target on Achaogen from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday. BidaskClub cut Achaogen from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th. Finally, Guggenheim initiated coverage on Achaogen in a research report on Tuesday, October 24th. They set a “buy” rating and a $17.00 price target for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $25.78.
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.